Wave Life Sciences, Inc. (WVE)
| Market Cap | 906.42M -24.9% |
| Revenue (ttm) | 65.37M -30.4% |
| Net Income | -202.47M |
| EPS | -1.08 |
| Shares Out | 197.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 531,312 |
| Open | 4.670 |
| Previous Close | 4.670 |
| Day's Range | 4.575 - 4.720 |
| 52-Week Range | 4.575 - 21.730 |
| Beta | -1.30 |
| Analysts | Strong Buy |
| Price Target | 18.53 (+302.83%) |
| Earnings Date | Jul 30, 2026 |
About WVE
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscula... [Read more]
Financial Performance
In 2025, Wave Life Sciences's revenue was $42.73 million, a decrease of -60.55% compared to the previous year's $108.30 million. Losses were -$204.38 million, 110.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for WVE stock is "Strong Buy." The 12-month stock price target is $18.53, which is an increase of 302.83% from the latest price.
News
Wave Life Sciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
RNA editing has advanced with highly specific, durable correction in clinical programs like AATD and PNPLA3, supported by chemistry innovations and new trial designs. The Inhibin E program is progressing in obesity and cardiometabolic disease, with data and regulatory milestones expected this year.
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
The discussion highlighted rapid progress in RNA medicines, with INHBE showing promising fat loss and safety in obesity, and WVE-006 advancing for AATD with a biomarker-driven regulatory path. Strategic interest remains strong, and new studies will address combination and maintenance therapies.
Wave Life Sciences Transcript: Bank of America SMID Cap Virtual Conference
The conference highlighted advances in RNA-based therapeutics, with WVE-007 and AATD programs poised for significant milestones in the next year. Strategic partnerships and a strong cash position support ongoing clinical progress and expansion into cardiometabolic indications.
Wave Life Sciences announces completion of redomiciliation to Delaware
Wave Life Sciences (WVE) announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation.
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd.
Wave Life Sciences to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...
Wave Life Sciences price target lowered to $23 from $27 at Mizuho
Mizuho lowered the firm’s price target on Wave Life Sciences (WVE) to $23 from $27 and keeps an Outperform rating on the shares.
Wave Life Sciences price target raised to $22 from $21 at B. Riley
B. Riley raised the firm’s price target on Wave Life Sciences (WVE) to $22 from $21 and keeps a Buy rating on the shares. The lower price target reflects a…
Wave Life Sciences price target lowered to $12 from $15 at Wedbush
Wedbush lowered the firm’s price target on Wave Life Sciences (WVE) to $12 from $15 and keeps an Outperform rating on the shares. The firm notes the Q2 update included…
Wave Life Sciences price target lowered to $19 from $24 at Citi
Citi lowered the firm’s price target on Wave Life Sciences (WVE) to $19 from $24 and keeps a Buy rating on the shares.
Wave Life Sciences price target lowered to $26 from $36 at Clear Street
Clear Street lowered the firm’s price target on Wave Life Sciences (WVE) to $26 from $36 and keeps a Buy rating on the shares. The firm is modifying its model…
Wave Life Sciences Earnings Call Transcript: Q2 2026
Multiple RNAi and RNA editing programs advanced, with WVE-007 and WVE-006 showing strong clinical progress and regulatory engagement. Q2 revenue declined, expenses rose, and cash runway extends into Q3 2028. Key trials are enrolling well, with major data and regulatory milestones expected in the second half of 2026.
Wave Life Sciences Earnings release: Q2 2026
Wave Life Sciences released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Wave Life Sciences Quarterly report: Q2 2026
Wave Life Sciences has published its Q2 2026 quarterly earnings report on July 30, 2026.
Wave Life Sciences reports Q2 EPS (34c), consensus (30c)
Reports Q2 revenue $2.27M, consensus $7.1M. “Our second quarter performance reflects disciplined execution across the pipeline,” said Paul Bolno, President and Chief Executive Officer at Wave Life Sci...
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
Dosing underway in Phase 2a multidose portion of the INLIGHT TM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m 2) and comorbidities; trial will also inform WVE-00...
Wave Life Sciences Slides: Corporate presentation
Wave Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform...
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of R...
Wave Life Sciences initiates multidose portion of Inlight trial
Wave Life Sciences (WVE) announced it has initiated the Phase 2a multidose portion of the Inlight trial, a placebo-controlled study evaluating WVE-007, an investigational GalNAc-siRNA, as monotherapy ...
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing
Wave Life Sciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
At the midpoint of 2026, the platform is advancing differentiated RNA therapies, with WVE-007 showing strong body composition results and moving into phase II-A for obesity. RNA editing programs for AATD and PNPLA3 are progressing, with regulatory and clinical milestones expected this year.
Wave Life Sciences Transcript: Jefferies Global Healthcare Conference 2026
Key programs in obesity, AATD, and liver disease are advancing, with INHBE studies set to launch and focus shifting to body composition as a regulatory endpoint. Recent data show strong differentiation in fat loss and muscle preservation, and regulatory feedback for AATD is expected mid-year.